Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13786 | 0.69 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBDPP4KDM4E | |
| SCHEMBL569156 | 0.69 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBDPP4KDM4E | |
| SCHEMBL88005 | 0.67 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBDPP4KDM4E | |
| SCHEMBL3258454 | 0.67 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBDPP4KDM4E | |
| SCHEMBL88004 | 0.67 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBDPP4KDM4E | |
| SCHEMBL2343049 | 0.67 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2POLBDPP4KDM4E | |
| SCHEMBL277229 | 0.67 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL692534 | 0.65 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBDPP4LMNA | |
| SCHEMBL8985064 | 0.65 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBDPP4KDM4E | |
| SCHEMBL8845450 | 0.65 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBDPP4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | NEUROSEARCH A/S | 2008-09-18 | — | — | US | claimed |
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | NEUROSEARCH A/S | 2008-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227772-A1 | Diazabicyclic Aryl Derivatives as Nicotinic Acetylcholine Receptor Ligands | CHRNA6, CHRNA10, CHRNA2 | ALDH1A1 1094/4885SMN1; SMN2 364/4885POLB 3892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.